Page last updated: 2024-11-06

1,2-dipalmitoyl-3-phosphatidylethanolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2-dipalmitoyl-3-phosphatidylethanolamine: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65109
SCHEMBL ID2733807
MeSH IDM0050766

Synonyms (59)

Synonym
palmitin, 1,2-di-, phosphate, 2-aminoethyl ester, dl- (6ci)
1,2-dipalmitoyl-3-dl-glycerylphosphorylethanolamine
dl-a-cephalin dipalmitate
1,2-dipalmitoyl-rac-glycerophosphoethanolamine
ethanol, 2-amino-, dihydrogen phosphate (ester), monoester with 1,2-dipalmitin, dl- (8ci)
1,2-dihexadecanoyl-rac-glycero-3-phosphoethanolamine
dl-dipalmitoylphosphatidylethanolamine
1,2-dipalmitoyl-dl-3-glycerophosphatidylethanolamine
dl-b,g-dipalmitoyl-a-cephalin
a-cephalin, b,g-dipalmitoyl
(+-)-1-[[[(2-aminoethoxy)hydroxyphosphinoyl]oxy]methyl]ethane-1,2-diyl bishexadecanoate
1,2-dipalmitoylphosphatidylethanolamine
palmitin, 1,2-di-, 2-aminoethyl hydrogen phosphate, dl- (8ci)
dipalmitoyl cephalin
1,2-dipalmitoyl-dl-phosphatidylethanolamine
hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester, (+/-)-
dl-a-dipalmitoylphosphatidylethanolamine
1,2-dipalmitoyl glycerylphosphorylethanolamine
b,g-dipalmitoyl-dl-a-cephalin
5681-36-7
rac-phosphatidylethanolamine, 1,2-dipalmitoyl
1,2-dipalmitoyl-rac-glycero-3-phosphoethanolamine, synthetic, >=98%
1,2-dipalmitoyl-3-phosphatidylethanolamine
D-6049
1,2-dipalmitoyl-rac-glycero-3-phosphoethanolamine
D-6061
[(2r)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate
unii-hya85h5s0g
hya85h5s0g ,
einecs 227-142-8
1,2-dipalmitoylcephaline
(1)-1-((((2-aminoethoxy)hydroxyphosphinoyl)oxy)methyl)ethane-1,2-diyl bishexadecanoate
hexadecanoic acid, 1-((((2-aminoethoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl ester, (+-)-
l-|a,|a-dipalmitoyl-|a-cephalin
FT-0625216
.beta.,.gamma.-dipalmitoyl-dl-.alpha.-cephalin
dl-.alpha.-dipalmitoylphosphatidylethanolamine
rac-1,2-dipalmitoylglycero-3-phosphoethanolamine
dppe, dl-
dl-.alpha.-cephalin dipalmitate
SCHEMBL2733807
dipalmityl phosphatidylethanolamine
palmitin, 1,2-di-, 2-aminoethyl hydrogen phosphate
hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester
2-([(2-aminoethoxy)(hydroxy)phosphoryl]oxy)-1-[(palmitoyloxy)methyl]ethyl palmitate #
SLKDGVPOSSLUAI-UHFFFAOYSA-N
hexadecanoic acid, 1-[[[hydroxy(2-aminoethoxy)phosphinyl]oxy]methyl]-1,2-ethanediyl ester
mfcd00036776
dipalmitoyl-phosphoethanolamine
dppe;l-beta,gamma-dipalmitoyl-alpha-cephalin
DTXSID301016031
dipalmitoyl phosphatidylethanolamine;1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine
BCP34415
Q27280160
STARBLD0009765
PD043169
SY057796
3-[[(2-aminoethoxy)(hydroxy)phosphoryl]oxy]propane-1,2-diyl (2r)-dipalmitate
pe 16:0_16:0

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Physiologically based pharmacokinetic (PBPK) models were developed for design and optimization of liposome therapy for treatment of overdoses of tricyclic antidepressants and local anesthetics."( A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man.
Chauhan, A; Howell, BA, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (362)

TimeframeStudies, This Drug (%)All Drugs %
pre-199063 (17.40)18.7374
1990's106 (29.28)18.2507
2000's113 (31.22)29.6817
2010's77 (21.27)24.3611
2020's3 (0.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.65 (24.57)
Research Supply Index5.92 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.27%)5.53%
Reviews3 (0.81%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other366 (98.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]